Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

Automated Colony Isolation

November 3, 2011 11:55 am | Product Releases | Comments

Hudson Robotics Inc.’s RapidPick ACIS Automated Colony Isolation System has samples of strains of bacteria, which are plated in sterile colony plates.


Slide Management System

November 3, 2011 11:51 am | Product Releases | Comments

Leica Microsystems’s clinical workflow solution combines the Digital Image Hub Enterprise with the SlidePath Gateway.


Automating Sample Preparation

November 3, 2011 11:48 am | Product Releases | Comments

Biologic Formulation Workflow by Freeslate Inc. automates sample preparation and stressing in addition to formulation analysis.


BAC Resin

November 3, 2011 7:53 am | Drug Discovery & Development | Product Releases | Comments

BAC BV, a provider of antibody based affinity purification technology, announced the addition of a bioprocess affinity chromatography resin to GE Healthcare Life Sciences' portfolio of custom-designed media.


High-Resolution Imaging

November 3, 2011 7:21 am | Product Releases | Comments

Applied Precision Inc. has launched the DeltaVision OMX Blaze, a research microscopy system designed to reach the next level in the evolution of super-resolution imaging by employing an ultra-fast illumination module and high-speed camera technologies.


Caliper Working with Pfizer on Drug Safety

November 3, 2011 6:53 am | News | Comments

Caliper Life Sciences, Inc. announced that its Caliper Discovery Alliances and Services unit has launched a new services offering developed in collaboration with Pfizer Inc.


Analysts Predict Sanofi Surge Past Pfizer

November 3, 2011 6:41 am | News | Comments

After nine years as the world’s biggest maker of medicines, Pfizer is set to cede its crown next year to a company that a decade ago few would have predicted to be leading the pharma league tables – Sanofi.


Pluristem Announces Positive PLX-PAD Data

November 3, 2011 6:32 am | News | Comments

PLX-PAD cells from Pluristem Therapeutics, Inc. met all the clinical studies’ protocol endpoints, demonstrating a safe immunologic profile at all dosage levels and found to be potentially effective in treating patients suffering from critical limb ischemia.


FDA Grants Lupuzor Fast Track Status

November 3, 2011 6:24 am | News | Comments

Following ImmuPharma’s Investigational New Drug filing with the FDA and the successful completion of a Phase 2b study, the FDA has granted Lupuzor Fast Track designation.


FDA Panel Backs Expanded Vytorin Use

November 3, 2011 6:18 am | News | Comments

Federal health experts are recommending that use of Merck's blockbuster cholesterol drug Vytorin be expanded to patients with kidney disease, but not those with late-stage disease who are on dialysis.


P & G Combining Medical Unit with Teva

November 3, 2011 6:16 am | by Christina Rexrode | News | Comments

Procter & Gamble Co. said that it has combined some of its drug units with Jerusalem-based Teva Pharmaceutical Industries Ltd., a move that should help the companies expand in China and other emerging markets.


GSK Agrees to $3B Settlement Deal

November 3, 2011 6:12 am | News | Comments

Drug maker GlaxoSmithKline PLC said that it has agreed in principle with the United States government on a $3 billion settlement of investigations of the company's sales and marketing practices.


Lilly CEO Wants Benefits/Risk Assessments

November 2, 2011 12:54 pm | News | Comments

To sustain medical innovation, the U.S. Food and Drug Administration must accelerate the adoption of a benefit-risk framework to inform decision-making in the regulatory process.


Regulus Therapeutics Gains Additional Patent Coverage

November 2, 2011 12:31 pm | News | Comments

Regulus Therapeutics Inc. announced that the Australian Patent Office has granted claims in the ‘Sarnow’ patent series for microRNA-122 therapy in the treatment of hepatitis C viral infections.

Study Shows How H.plylori Causes Cell Death

November 2, 2011 12:14 pm | News | Comments

Researchers have figured out how Helicobacter pylori attacks a cell’s energy infrastructure, sparking a series of events in the cell that ultimately lead it to self-destruct.


You may login with either your assigned username or your e-mail address.
The password field is case sensitive.